Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)

Market Cap	7.98B +42.4%
Revenue (ttm)	1.77B -2.9%
Net Income	14.22M -47.3%
EPS	0.04 -46.7%
Shares Out	396.81M
PE Ratio	561.34
Forward PE	n/a
Dividend	0.03 (0.14%)
Ex-Dividend Date	Jun 25, 2025

Volume	5,749,398
Average Volume	9,140,321
Open	20.71
Previous Close	20.82
Day's Range	20.03 - 20.76
52-Week Range	11.63 - 28.79
Beta	0.84
RSI	41.46
Earnings Date	Apr 29, 2026

About SHE:301246

Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, guanine, diacetyl guanine, and diacetylacyclovir; organic chemical raw materials comprising glyoxal, and oxalic acid; and new energy materials...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 2,169
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301246

Financial Performance

In 2024, SHE:301246's revenue was 1.77 billion, a decrease of -13.83% compared to the previous year's 2.05 billion. Earnings were 51.47 million, a decrease of -40.96%.